Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579159 | 1.00 | PPARD (0.45) | PPARDPTGER1 | |
| SCHEMBL29579677 | 1.00 | PPARD (0.45) | PPARDPTGER1 | |
| SCHEMBL20214067 | 1.00 | PPARD (0.45) | PPARDPTGER1 | |
| SCHEMBL20214265 | 0.95 | PTGER1 (0.43) | PPARDPTGER1 | |
| SCHEMBL20213972 | 0.94 | PTGER1 (0.44) | PPARDPTGER1 | |
| SCHEMBL29579307 | 0.93 | PTGER1 (0.43) | PPARDPTGER1 | |
| SCHEMBL20214550 | 0.93 | PTGER1 (0.43) | PPARDPTGER1 | |
| SCHEMBL29579136 | 0.93 | PTGER1 (0.41) | PPARDPTGER1 | |
| SCHEMBL20214502 | 0.93 | PTGER1 (0.41) | PPARDPTGER1 | |
| SCHEMBL20213973 | 0.92 | PPARD (0.43) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | claimed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | claimed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | claimed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | claimed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | claimed |
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112770813-A | Methods of treating cancer with substituted pyrrole and pyrazole compounds and diagnosing cancer sensitive to treatment with substituted pyrrole and pyrazole compounds | 班塔姆制药有限责任公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3548482-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bantam Pharmaceutical, LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102453-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BANTAM PHARMACEUTICAL, LLC (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | KRAS, TP53, CCNI | PPARD 933/4885PTGER1 614/4885 |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNI | PPARD 933/4885PTGER1 614/4885 |
| US-11192887-B2 | — | KRAS, TP53, CCNE1 | PPARD 1796/4885PTGER1 1070/4885 |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | PPARD 1206/4885PTGER1 980/4885 |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, NRAS | PPARD 715/4885PTGER1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.